431 related articles for article (PubMed ID: 29707987)
1. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review.
Bai Y; Li S; Jia Z; Ding Y; Gu C; Yang J
Urol Oncol; 2018 Feb; 36(2):79.e1-79.e10. PubMed ID: 29110942
[TBL] [Abstract][Full Text] [Related]
3. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
Messina C; Zanardi E; Boccardo F
Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
8. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
10. The Current State of Adjuvant Therapy Following Surgery for High-risk Renal Cell Carcinoma.
Ridyard DG; Buller DM; Ristau BT
Eur Urol Focus; 2019 Nov; 5(6):935-938. PubMed ID: 30975537
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
[TBL] [Abstract][Full Text] [Related]
13. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
14. The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.
Dibajnia P; Cardenas LM; Lalani AA
Hum Vaccin Immunother; 2023 Dec; 19(1):2178217. PubMed ID: 36775257
[TBL] [Abstract][Full Text] [Related]
15. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy in renal cell carcinoma.
Massari F; Di Nunno V; Ciccarese C; Graham J; Porta C; Comito F; Cubelli M; Iacovelli R; Heng DYC
Cancer Treat Rev; 2017 Nov; 60():152-157. PubMed ID: 28992528
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K; Berthold DR
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
[TBL] [Abstract][Full Text] [Related]
18. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses.
Ogasawara M; Miyashita M; Ota S
Ther Apher Dial; 2018 Jun; 22(3):266-277. PubMed ID: 29851270
[TBL] [Abstract][Full Text] [Related]
20. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
